Catalent Inc (CTLT) Director Buys $488,930.00 in Stock
Catalent Inc (NYSE:CTLT) Director John J. Greisch purchased 13,000 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were acquired at an average price of $37.61 per share, for a total transaction of $488,930.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
NYSE:CTLT traded down $0.99 during trading hours on Friday, reaching $36.32. The company had a trading volume of 858,489 shares, compared to its average volume of 919,208. Catalent Inc has a 1-year low of $34.24 and a 1-year high of $47.87. The company has a market capitalization of $5.42 billion, a PE ratio of 22.84, a PEG ratio of 2.33 and a beta of 1.44. The company has a current ratio of 2.05, a quick ratio of 1.61 and a debt-to-equity ratio of 1.44.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company had revenue of $551.80 million during the quarter, compared to the consensus estimate of $582.44 million. During the same period in the previous year, the company posted $0.21 earnings per share. Catalent’s revenue for the quarter was up 1.5% on a year-over-year basis. Equities research analysts predict that Catalent Inc will post 1.63 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research report on Monday, October 1st. UBS Group assumed coverage on Catalent in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 target price on the stock. JPMorgan Chase & Co. upped their target price on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Wednesday, August 29th. Morgan Stanley set a $46.00 target price on Catalent and gave the company a “buy” rating in a research report on Monday, December 3rd. Finally, Royal Bank of Canada set a $45.00 target price on Catalent and gave the company a “buy” rating in a research report on Friday, November 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Catalent currently has a consensus rating of “Buy” and an average target price of $48.00.
COPYRIGHT VIOLATION NOTICE: “Catalent Inc (CTLT) Director Buys $488,930.00 in Stock” was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.mareainformativa.com/news/2018/12/08/catalent-inc-ctlt-director-purchases-488930-00-in-stock-updated-updated-updated.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.